Skip to main content
SpringerLink
Log in

Author’s Reply to Woillard et al.: “Population Pharmacokinetics of Mycophenolic Acid: an Update”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

The Original Article was published on 19 June 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet. 2018;57(5):547–58.

    Article  PubMed  CAS  Google Scholar 

  2. Woillard JB, Debord J, Marquet P. Comment on “Population pharmacokinetics of mycophenolic acid: an update”. Clin Pharmacokinet. https://doi.org/10.1007/s40262-018-0687-9.

  3. Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50(1):1–24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol. 2012;73(5):727–40.

    Article  PubMed  CAS  Google Scholar 

  5. Wang XX, Liu W, Zheng T, Park JM, Smith DE, Feng MR. Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. Xenobiotica. 2017;47(8):697–704.

    Article  PubMed  CAS  Google Scholar 

  6. Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE. Development of improved dosing regimens for mycophenolate mofetil based on population pharmacokinetic analyses in adults with lupus nephritis. Eur J Drug Metab Pharmacokinet. 2017;42(6):993–1004.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada

    Tony K. L. Kiang

  2. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

    Mary H. H. Ensom

  3. Department of Pharmacy, Children’s and Women’s Health Centre of British Columbia, Vancouver, BC, Canada

    Mary H. H. Ensom

Authors
  1. Tony K. L. Kiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary H. H. Ensom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tony K. L. Kiang.

Ethics declarations

Conflict of interest

T Kiang and M Ensom have no conflicts of interest to declare relating to this manuscript.

Funding

No funding was received in the preparation of this manuscript.

Additional information

This author’s reply refers to the letter to the editor at https://doi.org/10.1007/s40262-018-0687-9.

This reply refers to the original article available at https://doi.org/10.1007/s40262-017-0593-6.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kiang, T.K.L., Ensom, M.H.H. Author’s Reply to Woillard et al.: “Population Pharmacokinetics of Mycophenolic Acid: an Update”. Clin Pharmacokinet 57, 1215–1216 (2018). https://doi.org/10.1007/s40262-018-0688-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-018-0688-8

Search

Navigation